Q-omics provides the consensus-scored CYCSP45 profile across patient tissues and cancer cell-line models. CYCSP45 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CYCSP45 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CYCSP45 RNA expression shows 12,418 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight LUAD, KIRC, and KICH as cancer lineages where CYCSP45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP45 survival associations across molecular data types. CYCSP45 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP45 RNA expression–survival associations across cancer types. High CYCSP45 expression shows unfavorable associations in LUAD, ESCA, UCS, MESO and ACC, but favorable associations in KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CYCSP45 RNA expression.
This table summarizes CYCSP45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP45 shows lower tumor expression in KIRC and COAD and higher tumor expression in KICH, LUAD, BRCA and LIHC. The KIRC box plot shows higher CYCSP45 RNA expression in normal versus tumor tissue (log2 FC = −0.229, t-test p = .002).
This table shows molecular features associated with CYCSP45 in patient tissues and cancer cell lines. In patient samples, CYCSP45 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set.
